Pitobrutinib price

Pitobrutinib is a kinase inhibitor indicated for the treatment of relapsed or refractory mantle cell lymphoma. This drug is suitable for patients whose disease cannot be controlled after at least two systemic treatments, including BTK inhibitors. It blocks the proliferation and survival signals of malignant cells by precisely inhibiting specific tyrosine kinases in lymphoma cells, thereby effectively controlling the development of the disease.

In pivotal clinical trials, pitobrutinib demonstrated remarkable efficacy, not only reducing the number of cancers in patients and even eliminating signs of cancer in some patients. For example, in one study, about 57% of patients with mantle cell lymphoma who had previously received treatment with a BTK inhibitor had a significant improvement in their condition after treatment with pitobrutinib, and 19% of them had no signs of cancer. At the same time, the drug's efficacy lasts for an average of 18 months, demonstrating its ability to control the disease in the long term.

In addition, pitobrutinib has a relatively high safety profile and is well tolerated by most patients. Of course, like other drugs, Pitobrutinib may cause some side effects, such as fatigue, musculoskeletal pain, etc., but these can usually be managed by adjusting the dose or taking other measures.

In general, with its unique mechanism, significant efficacy and good safety profile, pitobrutinib has brought new treatment options to patients with relapsed or refractory mantle cell lymphoma and greatly improved their quality of life.

Currently, Pitobrutinib is not available in China. Domestic patients who need Pitobrutinib can only purchase it abroad or contact regular overseas medical consulting companies. It is understood that there are original and generic versions of Pitobrutinib marketed overseas. The original version marketed overseas is the version marketed in the United States, with a specification of 50mg*30 tablets and a price of about 100,000 yuan. The price of the Laos generic version of Pitobrutinib marketed overseas is about 4,500 yuan. If you have more questions about pitobrutinib, please consult a regular overseas consulting company.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html